Inactive Instrument

Icosavax, Inc.

Equities

ICVX

US45114M1099

Biotechnology & Medical Research

Icosavax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022

May 16, 2022 at 04:05 pm EDT

Icosavax, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 23.53 million compared to USD 5.85 million a year ago. Basic loss per share from continuing operations was USD 0.6 compared to USD 2.11 a year ago.

Latest news about Icosavax, Inc.

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index	Feb. 19	CI
Icosavax, Inc.(NasdaqGS:ICVX) dropped from S&P TMI Index	Feb. 19	CI
Europe lacks direction on quiet Monday	Feb. 19	AN
AstraZeneca Completes $1 Billion Acquisition of Icosavax	Feb. 19	MT
AstraZeneca: successfully completes acquisition of Icosavax	Feb. 19	CF
AstraZeneca completes USD1.1 billion acquisition of Icosavax	Feb. 19	AN
AstraZeneca PLC completed the acquisition of Icosavax, Inc. from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management Company Limited and others.	Feb. 18	CI
Icosavax, Inc.(NasdaqGS:ICVX) dropped from S&P Global BMI Index	Feb. 18	CI
Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Biotechnology Index	Jan. 26	CI
Icosavax Insider Sold Shares Worth $1,670,460, According to a Recent SEC Filing	Jan. 08	MT
Guggenheim Downgrades Icosavax to Neutral From Buy	Jan. 02	MT
Icosavax, Inc.(NasdaqGS:ICVX) added to NASDAQ Biotechnology Index	Dec. 18	CI
FTSE 100 Edges Higher as European Markets Remain Cautious Ahead of Rate Calls	Dec. 13	DJ
Health Care Climbs on Deal Hopes -- Health Care Roundup	Dec. 12	DJ
Sector Update: Health Care Stocks Advance Late Afternoon	Dec. 12	MT
Trending : AstraZeneca Pushes Further Into Vaccines With Deal to Buy Icosavax	Dec. 12	DJ
Jefferies Downgrades Icosavax to Hold From Buy, Cuts Price Target to $15.50 From $30	Dec. 12	MT
Top Midday Gainers	Dec. 12	MT
Sector Update: Health Care Stocks Advance Tuesday Afternoon	Dec. 12	MT
FTSE 100 Ends Muted in Absence of U.S. Inflation Data Impetus	Dec. 12	DJ
London Stocks Flat as Markets Digest UK Wage Data, Upcoming Rate Decisions	Dec. 12	MT
Global markets live: Nokia, Oracle, AstraZeneca, Nvidia, Hasbro...	Dec. 12
William Blair Downgrades Icosavax to Market Perform From Outperform	Dec. 12	MT
FTSE 100 hits 8-week high on slowing wage growth, but construction sector drags	Dec. 12	RE
The only way is up…	Dec. 12

Chart Icosavax, Inc.

Duration

Period

More charts

Company Profile

Icosavax, Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on life-threatening respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. Its pipeline includes vaccine candidates targeting viral causes of pneumonia. It is developing these candidates for older adults, a patient population with high unmet need. Its lead vaccine candidate, IVX-A12, is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). It is also developing additional vaccine candidates as part of its strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults, including influenza and SARS-CoV-2.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.61%	43.84B
MODERNA, INC.	+6.04%	41.68B
LONZA GROUP AG	+45.04%	41.25B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+7.41%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.43%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.28%	12.29B
MEDPACE HOLDINGS, INC.	+26.58%	12.29B
UNITED THERAPEUTICS CORPORATION	+6.79%	11.15B

Other Biotechnology & Medical Research